Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline

Authors

Nadine M Tung
Dana Zakalik, Beaumont Health
Mark R Somerfield

Document Type

Article

Publication Date

9-10-2021

Publication Title

Journal of Clinical Oncology

Volume

39

Issue

26

First Page

2959

Last Page

2961

Recommended Citation

Tung NM, Zakalik D, Somerfield MR; Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J Clin Oncol. 2021 Sep 10;39(26):2959-2961. doi: 10.1200/JCO.21.01532. Epub 2021 Aug 3. PMID: 34343058.

DOI

10.1200/JCO.21.01532

ISSN

1527-7755

PubMed ID

34343058